Fertin Pharma Research And Development India Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 1.84 Cr
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 0.39%
- Profit Growth 25.59%
- Ebitda -1.75%
- Net Worth 12.91%
- Total Assets 18.51%
About Fertin Pharma Research And Development India
Company Details
-
Location
Goa, Goa, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U73100GA2011FTC013586
-
Company No.
013586
-
Company Classification
Private Limited Foreign Company Incorporated In India
-
Incorporation Date
28 Mar 2011
-
Date of AGM
30 Dec 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Goa
Industry
Who are the key members and board of directors at Fertin Pharma Research And Development India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Seshadri
|
Managing Director | 05-Sep-2011 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Michael Thomsen
|
Director | 14-Dec-2017 | Current |
|
Peter Halling
|
Director | 30-Sep-2020 | Current |
|
Lene Lind
|
Director | 20-Dec-2021 | Current |
Financial Performance of Fertin Pharma Research And Development India.
Fertin Pharma Research And Development India Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.39% increase. The company also saw a substantial improvement in profitability, with a 25.59% increase in profit. The company's net worth Soared by an impressive increase of 12.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fertin Pharma Research And Development India?
In 2020, Fertin Pharma Research And Development India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Vectura Fertin Pharma Private LimitedRavi Seshadri and Michael Thomsen are mutual person
-
Fertin India Private LimitedRavi Seshadri, Michael Thomsen and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fertin Pharma Research And Development India?
Fertin Pharma Research And Development India has a workforce of 26 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fertin Pharma Research And Development India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fertin Pharma Research And Development India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
